Patents by Inventor Mark K. Bennett

Mark K. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for enzyme inhibition
    Patent number: 8765745
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 1, 2014
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Compounds for enzyme inhibition
    Patent number: 8735441
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 27, 2014
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Substrate for Rpn 11 enzymatic activity
    Patent number: 8697837
    Abstract: The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: April 15, 2014
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Francesco Parlati, Monette Aujay, Mark K. Bennett
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20140100169
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 10, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20140080753
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 20, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20130338057
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 19, 2013
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Compounds for enzyme inhibition
    Patent number: 8609654
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: December 17, 2013
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig, Han-jie Zhou
  • COLLAGEN PRODUCTION COMPOUND
    Publication number: 20130108603
    Abstract: A topical skin care lotion includes materials for supplementing the production of collagen I and III includes a base of lipophillic or lipophobic material and at least one amino acid. The amino acids are alanine and glycine. Other components of the lotion include iron, vitamin C, manganese, silica and cherry fruit extract. Together, these components assist the body with the production of collagen and promote healing of damaged skin. Antioxidants are also provided to protect the skin from oxidative stress by ultraviolet sunlight and environmental hazards.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 2, 2013
    Inventor: Mark K. Bennett
  • Compounds for enzyme inhibition
    Patent number: 8431571
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: April 30, 2013
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION
    Publication number: 20130072422
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: March 1, 2011
    Publication date: March 21, 2013
    Inventors: Kevin D. Shenk, Francesco Paralati, Mark K. Bennett
  • Compounds for enzyme inhibition
    Patent number: 8357683
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: January 22, 2013
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20120088762
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: December 16, 2011
    Publication date: April 12, 2012
    Applicant: ONYX THERAPEUTICS, INC.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Compounds for enzyme inhibition
    Patent number: 8080545
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: December 20, 2011
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Compounds for enzyme inhibition
    Patent number: 8080576
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: December 20, 2011
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • COMBINATION THERAPY WITH PEPTIDE EPOXYKETONES
    Publication number: 20110236428
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Application
    Filed: October 21, 2009
    Publication date: September 29, 2011
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • NOVEL SUBSTRATE FOR RPN 11 ENZYMATIC ACTIVITY
    Publication number: 20100196346
    Abstract: The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.
    Type: Application
    Filed: July 20, 2009
    Publication date: August 5, 2010
    Applicant: Proteolix, Inc.
    Inventors: Francesco Parlati, Monette Aujay, Mark K. Bennett
  • Substrate for Rpn11 enzymatic activity
    Patent number: 7741432
    Abstract: The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: June 22, 2010
    Assignee: Proteolix, Inc.
    Inventors: Francesco Parlati, Monette Aujay, Mark K. Bennett
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20100144648
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: February 19, 2010
    Publication date: June 10, 2010
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20100144649
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: February 19, 2010
    Publication date: June 10, 2010
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Compounds for enzyme inhibition
    Patent number: 7691852
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: April 6, 2010
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-Jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig